AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 99 filers reported holding AVROBIO INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $2,897,000 | -75.9% | 325,891 | -65.6% | 0.10% | -76.2% |
| Q1 2021 | $12,029,000 | -7.5% | 947,928 | +1.6% | 0.40% | -11.7% |
| Q4 2020 | $13,001,000 | +41.3% | 932,627 | +31.9% | 0.45% | +10.8% |
| Q3 2020 | $9,204,000 | -29.6% | 706,882 | -5.6% | 0.41% | -33.9% |
| Q2 2020 | $13,066,000 | +16.9% | 748,770 | +4.2% | 0.62% | -12.0% |
| Q1 2020 | $11,176,000 | -13.4% | 718,247 | +12.0% | 0.70% | +33.0% |
| Q4 2019 | $12,911,000 | +42.6% | 641,387 | +0.0% | 0.53% | +31.4% |
| Q3 2019 | $9,055,000 | +6.6% | 641,265 | +22.7% | 0.40% | +19.0% |
| Q2 2019 | $8,497,000 | -26.3% | 522,590 | 0.0% | 0.34% | -27.1% |
| Q1 2019 | $11,523,000 | +85.6% | 522,590 | +40.2% | 0.46% | +59.3% |
| Q4 2018 | $6,208,000 | -66.9% | 372,865 | +3.1% | 0.29% | -54.2% |
| Q3 2018 | $18,753,000 | +211.2% | 361,537 | +71.4% | 0.63% | +190.4% |
| Q2 2018 | $6,026,000 | – | 210,982 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |